Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy

Breast Cancer Research and Treatment

Volumn 115, Issue 3, 2009, Pages 643-650

  Onitilo, Adedayo A ^a   McCarty, Catherine A ^a   Wilke, Russell A ^b   Glurich, Ingrid ^a   Engel, Jessica M ^a   Flockhart, David A ^c   Nguyen, Anne ^c   Li, Lang ^c   Mi, Deming ^c   Skaar, Todd C ^c   Jin, Yan ^c  

^a MARSHFIELD CLINIC   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptors; PvuII; Tamoxifen; Thromboembolization; XbaI

Indexed keywords

AROMATASE; CYTOCHROME P450; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS THROMBOEMBOLISM;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; AROMATASE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, ESTROGEN; RISK FACTORS; SURVIVAL RATE; TAMOXIFEN; VENOUS THROMBOEMBOLISM;

EID: 67349174180     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0264-2     Document Type: Article

References (35)

1. R Patel C Sharma V Jordan 2007 Optimizing the antihormonal treatment and prevention of breast cancer Breast Cancer 14 113 122 10.2325/jbcs.966
2. M Baum AU Budzar J Cuzick 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 10.1016/S0140-6736(02)09088-8
3. B Fisher JP Costantino DL Wickerham 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 97 1652 1662 (Pubitemid 41672231)
4. SR Deitcher MP Gomes 2004 The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review Cancer 101 439 449 10.1002/cncr.20347
5. Z Desta BA Ward NV Soukhova 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062 1075 10.1124/jpet.104.065607
6. MD Johnson H Zuo KH Lee 2004 Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 85 151 159 10.1023/B:BREA.0000025406.31193.e8
7. V Stearns MD Johnson JM Rae 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 (Pubitemid 38008898)
8. Y Jin Z Desta V Stearns 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39
9. MP Goetz JM Rae VJ Suman 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 10.1200/JCO.2005.03.3266
10. CX Ma AA Adjei OE Salavaggione 2005 Human aromatase: gene resequencing and functional genomics Cancer Res 65 11071 11082 10.1158/0008-5472.CAN-05-1218
11. C McCarty RA Wilke PF Giampietro 2005 Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank Pers Med 2 49 79 10.1517/17410541.2.1.49
12. RA Wilke RL Berg P Peissig 2007 Use of an electronic medical record for the identification of research subjects with diabetes mellitus Clin Med Res 5 1 7 10.3121/cmr.2007.726
13. DJ Schaid CM Rowland DE Tines 2002 Score tests for association between traits and haplotypes when linkage phase is ambiguous Am J Hum Genet 70 425 434 10.1086/338688
14. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451 1467 10.1016/S0140-6736(97)11423-4
15. B Fisher JP Costantino DL Wickerham 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371 1388 10.1093/jnci/90.18.1371 (Pubitemid 28439961)
16. JD Curb RL Prentice PF Bray 2006 Venous thrombosis and conjugated equine estrogen in women without a uterus Arch Intern Med 166 772 780 10.1001/archinte.166.7.772
17. VG Vogel JP Costantino DL Wickerham 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2727 2741 10.1001/jama.295.23.joc60074
18. DM Herrington TD Howard GA Hawkins 2002 Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease N Engl J Med 346 967 974 10.1056/NEJMoa012952
19. NI Ntukidem AT Nguyen V Stearns 2008 Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen Clin Pharmacol Ther 83 702 710 10.1038/sj.clpt.6100343
20. ZQ Hu H Ho T Skaar 2004 Thyroid binding globulin increase following tamoxifen treatment is associated with polymorphisms in the estrogen receptors gene Drug Metab Rev 36 suppl 1 30 Abstract
21. J Ellmén P Hakulinen A Partanen 2003 Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients Breast Cancer Res Treat 82 103 111 10.1023/B:BREA.0000003957.54851.11
22. BA Gower L Nyman 2000 Associations among oral estrogen use, free testosterone concentration, and lean body mass among postmenopausal women J Clin Endocrinol Metab 85 4476 4480 10.1210/jc.85.12.4476
23. N Abramson JP Costantino JE Garber 2006 Effect of factor V Leiden and prothrombin G20210->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial J Natl Cancer Inst 98 904 910 10.1093/jnci/djj262
24. A Decensi P Maisonneuve N Rotmensz 2005 Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial Circulation 111 650 656 10.1161/01.CIR.0000154545.84124.AC
25. C Duggan K Marriott R Edwards 2003 Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer J Clin Oncol 21 3588 3593 10.1200/JCO.2003.10.111
26. C Straczek E Oger MB Yon de Jonage-Canonico 2005 Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration Circulation 112 3495 3500 10.1161/CIRCULATIONAHA.105.565556
27. CJ Glueck P Wang RN Fontaine 1999 Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C) Am J Cardiol 84 549 554 10.1016/S0002-9149(99)00375-6
28. S Borges Z Desta L Li 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 10.1016/j.clpt.2006.03.013
29. AM Shearman LA Cupples S Demissie 2003 Association between estrogen receptor alpha gene variation and cardiovascular disease JAMA 290 2263 2270 10.1001/jama.290.17.2263
30. AM Shearman JA Cooper PJ Kotwinski 2005 Estrogen receptor alpha gene variation and the risk of stroke Stroke 36 2281 2282 10.1161/01.STR.0000181088. 76518.ec
31. AM Shearman JA Cooper PJ Kotwinski 2006 Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts Circ Res 98 590 592 10.1161/01.RES.0000210578. 62102.a6
32. Goetz MP, Rae JM, Suman VJ et al (2004) Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. Breast Cancer Res Treat 88:S35
33. Top 200 generic drugs by retail dollars in 2007. http://drugtopics. modernmedicine.com/drugtopics/data/articlestandard//drugtopics/102008/500218/ article.pdf. Accessed 11 July 2008
34. AN Freedman BI Graubard SR Rao 2003 Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention J Natl Cancer Inst 95 526 532 (Pubitemid 36511623)
35. KA Bauer FR Rosendaal JA Heit 2002 Hypercoagulability: too many tests, too much conflicting data Hematology (Am Soc Hematol Educ Program) 2002 353 368 10.1182/asheducation-2002.1.353